Forma-Celgene drug licensing deal could be worth $600M

04/2/2014 | American City Business Journals

Celgene secured the rights to license new therapeutic candidates identified by Forma Therapeutics' screening technique as part of an expanded deal between the firms. The new deal, which could be worth $600 million over the next few years, also gives Celgene the option to purchase Forma. "[T]his second agreement expands across Forma's preclinical and future clinical development efforts, encompassing numerous protein target families and covering a broad range of therapeutic areas," Forma President and CEO Steven Tregay said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA